Co-promotion gone bad: Cypress hands Savella to Forest

Share this article:
California-based Cypress Bioscience ended its co-promotion agreement with Forest Laboratories on Savella (milnacipran), a fibromyalgia drug approved in January 2009.

According to a company release dated August 4, Cypress will cut its workforce by 86%, or 123 employees, effective October 6, 2010. Forest will make a one-time, $2 million payment to Cypress, to “help facilitate this transition,” the release said.

In a further effort to reduce operating costs, Cypress will also “discontinue or sell” its personalized medicine services business by the end of September, said the release. Personalized medicine products include Avise PG, a blood test to see how well methotrexate—a cancer treatment—is metabolized in a patient's body; and Avise MCV, a blood test for diagnosing rheumatoid arthritis.

“Our withdrawal from the commercial market has been contemplated for some time now, and is part of our renewed strategic focus on CNS drug development,” said Jay Kranzler, chairman and CEO at Cypress.

Sales reps ostensibly under the employ of Cypress and Forest have been outspoken on the industry gossip site Café Pharma, before and after the announcement, with complaints ranging from too many reps on Savella, to inappropriate physician targets for fibromyalgia.

According to several Café Pharma posts, a Cypress conference call with employees broke the news about layoffs, and provided information about possible open positions with Forest. Frank Murdolo, VP investor relations at Forest, confirmed that Forest has “agreed to interview Cypress sales representatives that are interested in open positions in the Forest field sales force.”

In a Q1 2011 report dated July 20, 2010 (Forest's calendar year ends March 31), the company reported (April-June 2010) sales of Savella at $20.5 million. That figure is up from $9.6 million for April-June 2009, according to the Forest company report.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?